Under the agreement, Cellectricon will provide AstraZeneca with two of its new high throughput platforms, DynaflowHT, for ion channel screening. The DynaflowHT System will be launched and commercially available in 2009.
Jonas Ohlsson, CEO at Cellectricon, said: “Driven by solving bottlenecks in drug discovery, Cellectricon’s strategy is to bring state-of-the-art products for drug discovery and research to the market through world-class customer collaborations.”